cladribine has been researched along with Necrosis in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (66.67) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cros, E; Dumontet, C; Falette, N; Galmarini, CM; Jordheim, L; Puisieux, A; Voorzanger, N | 1 |
Hershko, C; Rosenmann, E; Zevin, S | 1 |
Guchelaar, HJ; Haanen, C; Koopmans, RP; Reutelingsperger, CP; Vermes, I | 1 |
3 other study(ies) available for cladribine and Necrosis
Article | Year |
---|---|
Influence of p53 and p21(WAF1) expression on sensitivity of cancer cells to cladribine.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Northern; Blotting, Western; Cell Cycle; Cell Survival; Cladribine; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Screening Assays, Antitumor; Gene Expression; Humans; Necrosis; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2003 |
Halogenoderma of the forearm caused by 2-chlorodeoxyadenosine treatment.
Topics: Adult; Antimetabolites, Antineoplastic; Chlorine; Cladribine; Drug Eruptions; Forearm; Humans; Hyperplasia; Infusions, Intravenous; Leukemia, Hairy Cell; Male; Necrosis; Skin | 1996 |
Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic model.
Topics: Antineoplastic Agents; Apoptosis; Cisplatin; Cladribine; Combined Modality Therapy; Cytarabine; Dose-Response Relationship, Drug; Flow Cytometry; Fluorouracil; Humans; Jurkat Cells; Models, Theoretical; Necrosis; Radiotherapy; Tumor Cells, Cultured | 1998 |